Pfizer’s Tofacitinib Under FDA Review
The U.S. Food and Drug Administration (FDA) is currently reviewing Pfizer’s experimental Rheumatoid Arthritis drug Tofacitinib to determine whether its benefits outweigh risks of cancerous cells and other infections. The FDA is in the early stages of reviewing the drug and will finalize their decision in August.
Benefits and Risks of Tofacitinib
- Benefit: Tofacitinib reduces inflammation of the joints caused by Rheumatoid Arthritis.
- Benefit: The drug is said to slow down structural damage within the joints.
- Risk: Tofacitinib was tied to a higher risk of cancerous cells, especially lymphoma.
- Risk: Risk of malignancies could get worse with higher doses or longer exposure to the drug.
Contact an Experienced Product Liability Attorney
Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. The Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/ or defective pharmaceuticals.
If you or a loved one have been injured by or have developed serious side-effects from the use of defective medications or pharmaceuticals, contact Thomas J. Henry immediately. We are available 24/7, nights and weekends.